Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy

Learn more about:
Related Clinical Trial
DMCRN-02-001: Assessing Pediatric Endpoints in DM1 Myotonic Dystrophy Type 1 and Resistance Exercise Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients Biomarker Development for Muscular Dystrophies Extracellular RNA Biomarkers of Myotonic Dystrophy Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1 Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1 Myotonic Dystrophy – Vascular and Cognition Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 Open Label Study in Adolescents and Children With Myotonic Disorders European Home Mechanical Ventilation Registry Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ? Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 Effects of a 12-week Strength Training Program in Men With Myotonic Dystrophy Type 1 Efficacy and Safety of DHEA for Myotonic Dystrophy Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1 Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 DM-IMT – Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respiratory Muscle Training in Patients With Myotonic Dystrophy Type 1 Venous Thromboembolism in DM1 Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients Factors Associated With Hypoventilation in the Myotonic Dystrophy, Progressive Profile Over 5 Years PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study) Children’s Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Observational Prolonged Trial in Myotonic Dystrophy Type 1 Venous Thromboembolism in Myotonic Dystrophy Type 1 Myotonic Dystrophy Type 1 Aerobic Exercise Study Multicenter Observational Study of Myotonic Dystrophy Type 1 DM1 Heart Registry – DM1 Respiratory Registry

Brief Title

Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy

Official Title

A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400mg Or 1000mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy

Brief Summary

      The purpose of this study is to determine whether Tideglusib is safe and efficacious in the
      treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy.
      The pharmacokinetics of tideglusib and its primary metabolite will also be investigated.
    


Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Incidence of Adverse events (AEs), including serious adverse events (SAEs), between baseline to end of study.


Condition

Myotonic Dystrophy 1

Intervention

Tideglusib

Study Arms / Comparison Groups

 Cohort 1 - Tideglusib
Description:  1000 mg tideglusib, orally, once daily

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

16

Start Date

July 20, 2016

Completion Date

January 2018

Primary Completion Date

January 2018

Eligibility Criteria

        Inclusion Criteria:

          -  Adolescents or adults with diagnosis of congenital or juvenile-onset type 1 myotonic
             dystrophy (DM-1)

          -  Diagnosis must be genetically confirmed

          -  Subjects must be male or female aged 12 years to 45 years

          -  Subjects must have a Clinical Global Impression - Severity (CGI-S) score of 4 or
             greater at Screening and Run-in (V2)

          -  Subjects must be ambulatory and able to complete the 10 metre walk/run test (splints
             allowed)

          -  Subject's legally authorized representative (LAR) must provide written informed
             consent and there must be written consent or assent (as age applicable and
             developmentally appropriate) by the subject before any study-related procedures are
             conducted

        Exclusion Criteria:

          -  Non-ambulatory (full time) wheel chair user

          -  Receiving stimulant medication

          -  Receiving other medications/therapies not stable (changed) within 4 weeks prior to
             Run-in (V2)

          -  Medical illness or other concern which would cause investigator to conclude subjects
             will not be able to perform the study procedures or assessments or would confound
             interpretation of data obtained during assessment.

          -  Current enrolment in a clinical trial of an investigational drug or enrolment in a
             clinical trial of an investigational drug in the last 6 months

          -  Women of child bearing potential who are pregnant, lactating or not willing to use a
             protocol defined acceptable contraception method if sexually active and not surgically
             sterile.

          -  Gastrointestinal disease which may interfere with the absorption, distribution,
             metabolism or excretion of the study medication and impact the interpretability of the
             study results

          -  Current clinically significant (as determined by the investigator) cardiovascular,
             renal, hepatic, endocrine or respiratory disease

          -  Clinically significant heart disease (in the opinion of the investigator) or second or
             third degree heart block, atrial flutter, atrial fibrillation, ventricular
             arrhythmias, or is receiving medication for treatment of a cardiac arrhythmia

          -  A history of chronic liver disease with current out of range values for Alanine
             transaminase (ALT), clinically relevant hepatic steatosis or other clinical
             manifestations of ongoing liver disease

          -  A history of significant drug allergy (such as Steven-Johnson syndrome, anaphylaxis)

          -  A history of alcohol or substance use disorders
      

Gender

All

Ages

12 Years - 45 Years

Accepts Healthy Volunteers

No

Contacts

Grainne Gorman, MB BCh BAO LRCP&SI MRCP FRCP, , 

Location Countries

United Kingdom

Location Countries

United Kingdom

Administrative Informations


NCT ID

NCT02858908

Organization ID

AMO-02-MD-2-001

Secondary IDs

2016-000067-16

Responsible Party

Sponsor

Study Sponsor

AMO Pharma Limited


Study Sponsor

Grainne Gorman, MB BCh BAO LRCP&SI MRCP FRCP, Principal Investigator, Institute of Neuroscience, Newcastle University.


Verification Date

December 2018